Local Pharmacokinetics and Tolerability of Bimatoprost Applied to the Scalp of Male Patients With Androgenetic Alopecia

Study Identifier
1666-101-012
CT.gov Identifier
NCT02848300
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact

844-663-3742 or [email protected]

Study Complete

Study Details

Medical Condition
  • Hair Loss - Other
    • Study Drug
  • Bimatoprost 1% Formulation A
  • Bimatoprost 1% Formulation B
    • Phase
    Phase 1
    Sex
    Male
    Age
    18 - 49 Years
    Inclusion and Exclusion Criteria
    Inclusion Criteria:
    -Patients with mild to moderate Androgenetic Alopecia of the vertex area of the scalp.
    Exclusion Criteria:
    * Patients with uncontrolled systemic disease * History of significant cardiovascular disease * Scarring disease, infection, or abnormality of the scalp or hair shaft or systemic disease that could cause temporary hair loss (eg, seborrheic dermatitis, psoriatic dermatitis, alopecia areata, cicatricial alopecia, uncontrolled hyperthyroidism/hypothyroidism, tinea infections, and genetic disorders) * Patients who have received hair transplants or have had scalp reductions * Abnormal bone biomarker laboratory results.

    Protocol Summary

    This study will evaluate the skin pharmacokinetics and tolerability of bimatoprost Formulation A and Formulation B following 14 days of once daily topical administration in male participants with androgenetic alopecia (AGA).

    Study Locations

    Location
    Status
    Location
    DermResearch, LLC
    Austin, Texas, United States, 78759
    Status
    Not applicable